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Mild systemic inflammation 
enhances response 
to OnabotulinumtoxinA in chronic 
migraineurs
Yago Leira1,2,3,4*, Clara Domínguez5, Pablo Ameijeira2, Esteban López‑Arias4, 
Paulo Ávila‑Gómez4, María Pérez‑Mato6, Tomás Sobrino4, Francisco Campos4, 
Juan Blanco1,2,7 & Rogelio Leira4,5,7
The anti‑inflammatory effect of OnabotulinumtoxinA (OnabotA) has been a matter of discussion for 
many years. In chronic migraine, however, increased pro‑inflammatory state is associated with good 
response to OnabotA. We aimed to investigate whether a mild systemic inflammatory state elicited by 
a common oral infection (periodontitis) could enhance treatment response to OnabotA. In this study, 
we included 61 chronic migraineurs otherwise healthy treated with OnabotA of which 7 were poor 
responders and 54 good responders. Before receiving OnabotA therapy, all participants underwent 
a full‑mouth periodontal examination and blood samples were collected to determine serum levels 
of calcitonin gene‑related peptide (CGRP), interleukin 6 (IL‑6), IL‑10 and high sensitivity C‑reactive 
protein (hs‑CRP). Periodontitis was present in 70.4% of responders and 28.6% of non‑responders 
(P = 0.042). Responders showed greater levels of inflammation than non‑responders (IL‑6: 15.3 ± 8.7 
vs. 9.2 ± 4.7 ng/mL, P = 0.016; CGRP: 18.8 ± 7.6 vs. 13.0 ± 3.1 pg/mL, P = 0.002; and hs‑CRP: 3.9 ± 6.6 vs. 
0.9 ± 0.8 mg/L, P = 0.003). A linear positive correlation was found between the amount of periodontal 
tissue inflamed in the oral cavity and markers of inflammation (IL‑6: r = 0.270, P = 0.035; CGRP: 
r = 0.325, P = 0.011; and hs‑CRP: r = 0.370, P = 0.003). This report shows that in presence of elevated 
systemic inflammatory markers related to periodontitis, OnabotA seems to reduce migraine attacks. 
The changes of scheduled inflammatory parameters after treatment and subsequent assessment 
during an adequate period still need to be done.
Periodontitis is a chronic infection affecting the gums that is characterized by gingival tissue breakdown, oral 
bone destruction and ultimately tooth loss. This oral infection does not only produce a local inflammatory reac-
tion in the gingiva with upregulation of pro-inflammatory cytokines such as interleukin 6 (IL-6) and downregula-
tion of anti-inflammatory cytokines such as IL-10 but also is considered an important contributor to the body’s 
overall inflammatory burden. It has been hypothesized that the ulcerated periodontal epithelium in periodontitis 
patients may act as an entrance to the bloodstream of IL-6 and many other pro-inflammatory molecules which 
evoke an acute-phase response in the liver resulting in the overexpression of systemic inflammatory mediators 
such as C-reactive protein (CRP), fibrinogen and serum amyloid  A1,2 or even specific proteins involved in the 
process of neurogenic inflammation [i.e., calcitonin gene-related peptide (CGRP)] typically seen in the physi-
opathology of head  pain3. Based on this, untreated periodontitis has been suggested to lead to a low-grade chronic 
systemic inflammatory state in both human and animal  studies4,5.
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Chronic migraine is a neurovascular disorder in which neuropeptides (e.g., CGRP, glutamate and substance 
P) and neurotransmitters are systemically released due to inadequate pain responses to peripheral chemical and 
mechanical  stimuli6. Additionally, peripheral stimulation of meningeal nociceptors may also lead to the release 
of pro-inflammatory cytokines that activate mast cells and result in regional  neuroinflammation6. Onabotuli-
numtoxinA (OnabotA) is the only prophylactic treatment specifically used for chronic migraine. It has been 
suggested that the mechanism of action of OnabotA is based on the blockage of inflammatory neuropeptides 
that are released from stimulated trigeminal sensory  neurons7.
Experimental studies using different models of inflammation and pain yielded to contradictory results regard-
ing the potential anti-inflammatory effect of  OnabotA8–11. Bach-Rojecky et al. showed a lack of anti-inflammatory 
effect of peripheral application of OnabotA in two models of experimental neurogenic inflammation namely car-
rageenan and  capsaicin8. On contrary, by using a formalin-induced inflammatory pain, Cui and co-workers were 
the first demonstrating a significant reduction in pain and oedema in the second phase of pain (inflammatory 
phase) but not in the first phase (acute pain phase) after OnabotA  injections9. In line with these results, Chuang 
et al. showed that OnabotA pre-treatment dose dependently decreased inflammatory-cell accumulation and 
cyclooxygenase-2 expression in a capsaicin-induced prostatitis rat  model10. Also, results from an organ culture 
study confirmed the ability of OnabotA to modify/reduce the expression of CGRP or cytokines in the trigeminal 
 ganglion11. Recent clinical evidence has been published supporting these experimental findings, where Onabot 
A was capable of reducing CGRP levels in peripheral blood in chronic  migraineurs12 and those with interictal 
pre-treatment increased concentrations of markers of neurogenic (CGRP)13,14 and systemic (acute-phase proteins 
such as pentraxin 3)13 inflammation responded better to this type of treatment.
It is reasonable to hypothesize, therefore, that mild systemic inflammation such as that observed in human 
periodontitis may enhance response to OnabotA in chronic migraineurs. To test this hypothesis, our aim was to 
evaluate whether those good responders to OnabotA presented high levels of inflammatory biomarkers compared 
to non-responders using a human model of low-grade systemic inflammation.
Methods
Study design. This is a secondary analysis with a cross-sectional design from previous observational stud-
ies from our group, which looked at the clinical and molecular relationship between periodontitis and chronic 
 migraine3,15.
Study population. For this analysis, we included sixty-one non-smoker adults in apparent good general 
health attending the Headache Unit of the University Clinical Hospital (Santiago de Compostela, Spain) with a 
diagnosis of chronic migraine (≥ 15 days per month with headache for at least 3 months)16 who were treated with 
pericranial OnabotA injections by a trained neurologist (RL) according to the Phase III REsearch Evaluating 
Migraine Prophylaxis Therapy (PREEMPT)  protocol17. Briefly, chronic migraineurs received 155–195 OnabotA 
units in 31–39 injections sites twice over two consecutive periods of 12 weeks13. When present, treatment with 
other prophylactic medications was not interrupted. Evaluation of efficacy was done by means of diaries com-
pleted by patients in the 3 months following the second dose of OnabotA in which they had to report the number 
of episodes of moderate-severe acute headache lasting more than 4 h (or shorter if treated with symptomatic 
drugs). We considered responders those patients that showed ≥ 50% reduction in frequency of headache and 
non-responders were patients with < 50% of reduction in headache  frequency13.
We excluded those participants aged 17 years or less, with 15 teeth or less (excluding third molars), who 
received periodontal treatment with or without systemic antibiotics in the last year, and who were pregnant or 
breastfeeding.
The study was approved by the Ethics Committee of the Servizo Galego de Saúde (ID: 2016/079) and per-
formed according to the Declaration of Helsinki of the World Medical Association (2008). The Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) guidelines were followed in this cross-sectional 
 study18. Written informed consent was obtained from each participant after full explanation of the procedures.
Migraine characteristics. Migraine characteristics including time evolution of chronic migraine (in 
months), frequency of migraine attacks (number/month), intensity of headaches (using the Visual Analogue 
Scale), presence of aura and allodynia were recorded.
Socio‑demographic, clinical and periodontal data. In addition to socio-demographic information 
(age, gender and education level) and body mass index (BMI: weight/height2), all participants received a full-
mouth periodontal examination by a trained periodontist (PA) as previously  described15. Full-mouth clinical 
periodontal measurements (i.e., six sites per tooth) from each participant including gingival pocket depth (PD), 
clinical attachment level (CAL), dental plaque accumulation, and gingival  bleeding19 were obtained just before 
OnabotA treatment was initiated using a calibrated University of North Carolina periodontal probe (UNC15, 
Hu-Friedy, Chicago, IL, USA). The presence of periodontitis was established when ≥ 2 interproximal sites with 
CAL ≥ 3 mm and ≥ 2 interproximal sites with PD ≥ 4 mm (not on the same tooth) or 1 site with PD ≥ 5 mm were 
 present20. Additionally, we calculated a measure of periodontitis activity, the periodontal inflamed surface area 
(PISA), which reflects the surface area of bleeding pocket epithelium in  mm221. PISA was calculated as follows: 
(1) with the mean CAL and gingival recession we obtained the periodontal epithelial surface area (PESA) for 
each  tooth22; (2) the PESA value multiplied by the number of sites with bleeding upon probing results in the 
PISA for an specific tooth; (3) Full-mouth PISA is calculated for each participant (in  mm2) by the sum of the 
PISAs for each tooth.
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Samples collection and laboratory methodology. Fasting blood samples were obtained in the morn-
ing in a pain free period (at least 12 h from the last migraine attack) and before initiating OnabotA therapy. 
Subjects had not consumed anti-inflammatory or analgesic medication in the previous 72 h. In brief, after blood 
samples were taken and clotted, serum was obtained by centrifugation (15 min at 3000g) and stored at − 80 °C. 
Serum high sensitivity CRP (hs-CRP) was measure using an immunodiagnostic IMMULITE 2000 Systems (Sie-
mens Healthcare Diagnostics, Malvern, PA, USA) while IL-16 and IL-10 (BioLegend, San Diego, CA, USA) as 
well as CGRP (Cloud-Clone, Katy, TX, USA)] were measured by enzyme-linked immunosorbent assay tech-
nique following manufacturer instructions as previously  described3. All biochemical determinations were done 
in an independent laboratory blinded to clinical data and treatment response.
Statistical analysis. Mean values and standard deviation (mean ± SD) were calculated for continuous vari-
ables and compared using independent t test after normality was confirmed by Kolmogorov–Smirnov test. Non-
normally distributed continuous variables were expressed as median  [P25,  P75] and compared with Mann–Whit-
ney U test. Categorical data were reported as percentages (%) and compared by Fisher’s exact test. Parametric 
correlation analyses between clinical periodontal parameters and biomarkers among chronic migraine patients 
were performed using Pearson’s correlation coefficient. Logistic regression models were performed to test poten-
tial associations between periodontitis and response to treatment. All tests were performed at a significance level 
of α = 0.05. All data analyses were performed with IBM SPSS Statistics 20.0 software for Mac.
No formal sample size calculation was performed, as this is a secondary analysis. However, a post-hoc power 
analysis based on the results obtained from the present study and using our primary outcome (i.e., IL-6 concen-
trations) confirmed a 90% power to detect a 6.0 pg/mL difference in IL-6 between study groups (responders vs. 
non responders), with a SD of 2.1. Sufficient study statistical power (> 90%) was also confirmed when hs-CRP 
[effect (SD): 3.0 (0.9 mg/L)], IL-10 [effect (SD): 1.5 (0.4) pg/mL] or CGRP [effect (SD): 5.8 (1.6) pg/mL] were 
used for the calculation. All statistical power analysis were done with Macro !NSize for PASW Statistics (http://
www.metod o.uab.cat/macro s.htm).
Results
Baseline characteristics. Subjects with good (N = 54) and poor (N = 7) response were similar in terms of 
age (P = 0.609), gender (P = 0.885), low educational level (P = 0.594), BMI (P = 0.491), and migraine characteris-
tics (number of migraine attacks/month: P = 0.411; intensity of migraine attacks: P = 0.264; presence of allodynia: 
P = 0.655; and presence of aura: P = 0.339). Only the time of chronic migraine evolution was statistically signifi-
cant less in responders than non-responders (24.0 ± 14.2 vs. 34.5 ± 9.8 months, P = 0.032) (Table 1).
Clinical periodontal parameters. Periodontitis was present in 70.4% of responders and 28.6% of non-
responders (P = 0.042). Those with good response to OnabotA had worse periodontal condition compared to 
non-responders (PD: 3.2 ± 0.6 vs. 2.5 ± 0.7  mm, P = 0.006; CAL: 3.8 ± 0.9 vs. 2.9 ± 0.8  mm, P = 0.033; gingival 
bleeding: 54.1 ± 28.4 vs. 24.4 ± 12.4%, P < 0.001; PISA: 630.0 ± 558.7 vs. 360.1 ± 214.0 mm2, P = 0.025) although 
the levels of plaque accumulation were similar between groups (38.0 ± 22.2 vs. 30.5 ± 23.6%, P = 0.453). In the 
same line, those participants with better response presented higher number of periodontal pockets with PD 
≥ 6 mm and CAL ≥ 5 mm compared to those with worse response to OnabotA (Table 1). Regression analy-
sis showed that diagnosis of periodontitis was linked to good response to OnabotA  (ORunadjusted = 5.9; 95% CI 
1.0–33.8, P = 0.045). After adjusting for time of evolution, however, the magnitude of this association increased 
 (ORadjusted = 8.9; 95% CI 1.2–61.7, P = 0.026).
Biomarkers. Responders showed greater levels of inflammation than non-responders (CGRP: 18.8 ± 7.6 vs. 
13.0 ± 3.1 pg/mL, P = 0.002; hs-CRP: 3.9 ± 6.6 vs. 0.9 ± 0.8 mg/L, P = 0.003; IL-6: 15.3 ± 8.7 vs. 9.2 ± 4.7 ng/mL, 
P = 0.016). On contrary, the anti-inflammatory mediator IL-10 was lower in the group of responders than non-
responders subjects (2.1 ± 1.1 vs. 3.6 ± 1.1 pg/mL, P = 0.010). When concentrations of inflammatory biomark-
ers were analysed according to periodontal status, patients with periodontitis presented statistically significant 
higher levels of IL-6 and CGRP than those without periodontitis (17.0 ± 8.5 vs. 10.0 ± 6.5 ng/mL, P = 0.002 and 
19.5 ± 6.9 vs. 15.2 ± 7.8 pg/mL, P = 0.035; respectively) but differences for hs-CRP did not reach statistical signifi-
cance between groups (3.9 ± 7.0 vs. 2.8 ± 4.8 mg/L, p = 0.465). IL-10 concentrations were statistically significant 
decreased in the periodontitis group compared to those periodontally healthy (2.0 ± 1.0 vs. 3.0 ± 1.2  pg/mL, 
P = 0.002).
Correlation analysis. Correlations between clinical periodontal parameters and biomarkers of inflamma-
tion are shown in Table 2. PISA (a measure of active periodontitis) was positively correlated with inflammatory 
markers whilst the opposite was found with IL-10 (Fig. 1).
Discussion
In this study, we found that in chronic migraineurs with mild systemic inflammation elicited by a common oral 
infection (i.e., periodontitis) had a better response to OnabotA compared to those without signs of gingival 
infection. This finding, thus, supports a potential anti-inflammatory effect of OnabotA in the treatment of 
chronic migraine.
Inflammation is a key element in chronic migraine. CGRP expressed in central and peripheral nervous system 
modulates nociceptive input and mediates neurogenic inflammation through activation of the trigeminovascular 
 system23. CGRP is released inducing vasodilation around cerebral vessels resulting in migraine-like  pain24 and 
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it has been shown that repeated activation of trigeminovascular system may produce migraine chronification 
due to central pain  sensitization25. Besides the role of CGRP as a potential biomarker of chronic  migraine26, this 
vasoactive neuropeptide is considered as a predictor of good response to  OnabotA13,14. Even though the mecha-
nism of action by which OnabotA reduces the number and severity of headaches in chronic migraineurs is not 
fully understood, it might involve the blockage of the release of neuropeptides and other inflammatory media-
tors in sensory neurons that promote peripheral sensitization within trigeminal  glia27. Additionally, at the level 
Table 1.  Characteristics of chronic migraineurs according to treatment response (N = 61). BMI body mass 
index, CAL clinical attachment level, CAL5 number of periodontal pockets with CAL ≥ 5 mm, FMBS full-
mouth gingival bleeding score, FMPS full-mouth plaque score, PISA periodontal inflamed surface area, PD 
pocket depth, PD6 number of periodontal pockets with PD ≥ 6 mm.
Variable Responders (N = 54) Non-responders (N = 7) P value
Age (years) 49.0 ± 9.4 50.8 ± 3.3 0.609
Females, n (%) 53 (98.1) 7 (100) 0.885
Low education level, n (%) 25 (46.3) 3 (42.9) 0.594
BMI (kg/m2) 26.0 [24.7, 28.0] 24.0 [22.0, 27.2] 0.259
Clinical periodontal parameters
FMPS (%) 38.0 ± 22.2 30.5 ± 23.6 0.453
FMBS (%) 54.1 ± 28.4 24.4 ± 12.4 < 0.001
Mean PD (mm) 3.2 ± 0.6 2.5 ± 0.7 0.006
PD6, n 12.3 ± 15.1 1.6 ± 2.4 < 0.001
Mean CAL (mm) 3.8 ± 0.9 2.9 ± 0.8 0.033
CAL5, n 33.6 ± 28.0 15.7 ± 10.8 0.005
Mean PISA  (mm2) 630.0 ± 558.7 360.1 ± 214.0 0.025
Migraine characteristics
Time of evolution (years) 24.0 ± 14.2 34.5 ± 9.8 0.032
Frequency (nº attacks/month) 19.6 ± 5.4 21.4 ± 3.9 0.411
Intensity (VAS) 8.5 [8.0, 10.0] 8.0 [7.0, 9.0] 0.250
Aura, n (%) 0 (0.0) 4 (7.4) 0.339
Allodynia, n (%) 34 (68.0) 5 (83.3) 0.655
Analgesic overuse, n (%) 13 (25.5) 2 (33.3) 0.648
Preventive treatment in the last 3 months, n (%)
Topiramate 17 (32.1) 1 (14.3) 0.663
β-Blockers 20 (37.0) 4 (57.1) 0.418
Amitriptyline 22 (40.7) 4 (57.1) 0.409
Flunarizine 7 (13.0) 1 (814.3) 0.647
Antihypertensives 0 (0.0) 1 (14.3) 0.115
Migraine acute treatment, n (%)
Triptans 42 (77.8) 5 (71.4) 0.655
Non-steroidal anti-inflammatory drugs 50 (92.6) 5 (71.4) 0.136
Opioids 13 (24.1) 0 (0.0) 0.328
Table 2.  Pearson’s correlation coefficient for clinical periodontal parameters and biomarkers (N = 61). CAL 
clinical attachment level, CAL5 number of periodontal pockets with CAL ≥ 5 mm, FMBS full-mouth gingival 
bleeding score, FMPS full-mouth plaque score, PD pocket depth, PD6 number of periodontal pockets with 
PD ≥ 6 mm.
PD (mm) CAL (mm) FMBS (%) FMPS (%) PD6 CAL5
IL-6 (ng/mL) 0.297 0.243 0.464 0.375 0.241 0.387
P-value 0.020 0.059 < 0.001 0.003 0.061 0.002
IL-10 (pg/mL) − 0.406 − 0.455 − 0.234 − 0.186 − 0.378 − 0.404
P-value 0.001 < 0.001 0.070 0.151 0.003 0.001
CGRP (pg/mL) 0.313 0.294 0.363 0.311 0.288 0.306
P-value 0.014 0.021 0.004 0.015 0.024 0.016
hs-CRP (mg/L) 0.234 0.215 0.147 0.303 0.145 0.180
P-value 0.070 0.096 0.258 0.018 0.267 0.166
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of the spinal cord OnabotA could inhibit release of pro-inflammatory mediators which results in deactivation 
of second-order nociceptive neurons and glia cells involved in central  sensitization27. Contradictory to these 
hypotheses, evidence from different animal models did not find an association between reduction of pain and 
inflammation after OnabotA injection, thus, questioning the anti-inflammatory effect of this treatment  modality8.
Periodontitis is able to induce a systemic inflammatory response with high levels of pro-inflammatory 
cytokines and acute-phase reactants measured in the peripheral  blood2. A recent case–control study showed 
that subjects with periodontitis had two-fold increased risk for having chronic  migraine15. On top of that, another 
clinical study demonstrated that periodontal inflammation was associated with increased circulating levels of 
CGRP in chronic migraineurs and authors hypothesized that upregulation of IL-6 could mediate this  finding3. 
However, whether IL-6 induces CGRP overexpression or vice versa is still unknown as CGRP is capable of pro-
ducing inflammatory cytokines from lymphocytes and macrophages after lipopolysaccharide  infection28,29. In 
the present study, different periodontal parameters reflecting active disease (i.e., PD and PISA) were positively 
correlated with elevated levels of IL-6 and CGRP.
For the purpose of this study, we used a human model that mimics a sufficient mild systemic inflammatory 
response that allowed us to confirm the anti-inflammatory effect of OnabotA in chronic migraine as those 
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subjects with untreated periodontitis and increased concentrations of CGRP and IL-6 responded better to this 
therapy than those without periodontitis. We have to be very cautious, however, when interpreting these results. 
Periodontitis is an oral infection that has to be treated; otherwise, it would lead to tooth loss and diminished 
masticatory function. Also, it has a systemic impact increasing the risk not only of chronic migraine but also 
of other conditions such as cardiovascular/cerebrovascular diseases, diabetes, dementia, kidney disease, and 
rheumatic diseases among  others30. In our study, after periodontal examination those with a diagnosis of peri-
odontitis were immediately offered periodontal treatment or were recommended seeking for treatment. What 
is unknown is whether the effect observed in our study is maintained after evaluation of efficacy at 3 months. 
Another question to be answered would be if periodontal therapy could have an impact on migraine outcomes 
or OnabotA efficacy.
We have to acknowledge some limitations in relation to this investigation. Firstly, blood inflammatory mark-
ers were determined only prior to OnabotA injections. Future studies might include a post-treatment blood 
sample collection to assess whether these biomarkers are reduced or not as previously shown for  CGRP12. Sec-
ondly, although in apparent good general health, some of the patients could have other undiagnosed conditions 
linked to increased systemic inflammation. For instance, responders had higher BMI than non-responders and 
it is well-known that increased BMI often co-exists with low-grade chronic  inflammation31. Nevertheless, only 
two participants from our study (one from each study group) presented a BMI value ≥ 30 kg/m2 and could be 
considered as obese. Thirdly, study sample size is small in particular the number of non-responder was 7. This 
is because patients were recruited from a Headache Unit with experience treating chronic migraine subjects 
and most of them were good responders. Future trials with a formal sample size calculation including similar 
number of patients in each group are warranted. Another potential limitation could be the follow-up to assess 
treatment response in our patients (24 weeks after first injection). Although this follow-up is in accordance with 
the PREEMPT  protocol17, which measures the primary outcome at the same time, because after third injections 
patients could still show some  improvement32, further evidence is needed to confirm our findings in the long-
term (e.g., 56 weeks after first injection).
To conclude, the present data show that in presence of elevated systemic inflammatory markers related to 
periodontitis, OnabotA seems to reduce migraine attacks. The changes of scheduled inflammatory parameters 
after treatment and for an adequate period must be done.
Data availability
The dataset analysed during the current study are available from corresponding author on reasonable request.
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